MedPath

Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children

Not Applicable
Not yet recruiting
Conditions
Postoperative Pain
Registration Number
NCT07188779
Lead Sponsor
Rutgers, The State University of New Jersey
Brief Summary

The purpose of the research is to determine if RADA16 (also known as PuraStat®, PuraGel®, or PuraSinus®) improves patient outcomes following pediatric tonsillectomy procedures. Researchers will compare application of device RADA16 to application of no device to see if RADA16 works to treat post tonsillectomy hemorrhage.Participants will:

Undergo tonsillectomy procedure. Receive and fill out a survey sent via email every 2 days following their procedure for 15 days, plus an additional survey on day 30, and track their symptoms.

Detailed Description

This is a prospective study evaluating the impact of intraoperative RADA16 application on the postoperative course following pediatric tonsillectomy as it relates to pain, bleeding, readmission, and use of a rescue analgesic (ex., oxycodone). We propose a randomized controlled trial whereby patients undergoing tonsillectomy would either receive a standard analgesic regimen (postoperative acetaminophen and NSAIDs plus oxycodone as a supplemental analgesic) versus intraoperative RADA16 application plus a standard analgesic regimen.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
134
Inclusion Criteria

Children aged 3-17 years undergoing tonsillectomy +/- adenoidectomy CPT codes

  • 42820 (Tonsillectomy and adenoidectomy; younger than age 12)
  • 42821 (… age 12 or over)
  • 42825 (Tonsillectomy; primary or secondary; younger than age 12)
  • 42826 (… age 12 or over)
  • 42830 (Adenoidectomy, primary; younger than age 12)
  • 42831 (… age 12 or over)
  • 42835 (Adenoidectomy; secondary; younger than age 12)
  • 42836 (… age 12 or over)
Exclusion Criteria
  • Children with bleeding disorders or other hematologic malignancy or taking anticoagulant medications Developmental delay affecting pain reporting Children with known allergies to RADA16 components Children with prior tonsillectomy or tonsillotomy Children undergoing tonsillectomy with concern for cancer, Children taking opioids chronically prior to surgery, Anyone pregnant women, incarcerated individuals, children unable to speak English or Spanish

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Postoperative painFrom enrollment to post-operative day 30.

Pain assessed via the Wong Baker Faces scale. The primary outcome measure will be assessed via online survey on post-operative day one then subsequently every other day until post-operative day fifteen, with a final survey on day 30.

Secondary Outcome Measures
NameTimeMethod
Number of Participants with post-tonsillectomy hemorrhage who receive topical agentsFrom enrollment to post-operative day 30

Number of Participants with post-tonsillectomy hemorrhage who receive topical agents for management of post tonsillectomy hemorrhage

Number of Participants with post-tonsillectomy hemorrhage who require a return to the operating roomFrom enrollment to post-operative day 30

Number of Participants with post-tonsillectomy hemorrhage who require a return to the operating room for management of post tonsillectomy hemorrhage

Number of participants who require hospital readmission for post tonsillectomy hemorrhage managementFrom enrollment to post-operative day thirty

Number of participants who require readmission for management of post tonsillectomy hemorrhage

Number of participants who require a rescue analgesic for management following tonsillectomy procedureFrom enrollment to post-operative day 30

Number of participants who use a rescue analgesic following their tonsillectomy procedure

Days participants take to resume their regular diet post operationFrom enrollment to post-operative day 30

Recording how many days it takes for participants to return to their regular diet post operation

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.